MAPT and Alzheimer disease: Relatedly, a hypothetical model of AD biomarkers suggests that vascular dysfunction, such as changes in the cerebral blood flow (CBF) and blood–brain barrier, may contribute to the initial stages of the pathophysiological process in patients with AD, even before the emergence of Aβ and tau pathologies [6].